Comparing Innocoll Holdings PLC (INNL) and Eyegate Pharmaceuticals (EYEG)
Innocoll Holdings PLC (NASDAQ: INNL) and Eyegate Pharmaceuticals (NASDAQ:EYEG) are both small-cap pharmaceuticals – nec companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
Insider & Institutional Ownership
34.2% of Innocoll Holdings PLC shares are owned by institutional investors. Comparatively, 13.1% of Eyegate Pharmaceuticals shares are owned by institutional investors. 24.6% of Eyegate Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Innocoll Holdings PLC and Eyegate Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Innocoll Holdings PLC||N/A||N/A||N/A||($1.66)||-1.42|
|Eyegate Pharmaceuticals||$670,000.00||29.29||-$13.34 million||($1.30)||-0.88|
Innocoll Holdings PLC has higher revenue, but lower earnings than Eyegate Pharmaceuticals. Innocoll Holdings PLC is trading at a lower price-to-earnings ratio than Eyegate Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and price targets for Innocoll Holdings PLC and Eyegate Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Innocoll Holdings PLC||0||3||1||0||2.25|
Innocoll Holdings PLC currently has a consensus target price of $4.50, suggesting a potential upside of 91.49%. Eyegate Pharmaceuticals has a consensus target price of $7.33, suggesting a potential upside of 542.71%. Given Eyegate Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Eyegate Pharmaceuticals is more favorable than Innocoll Holdings PLC.
This table compares Innocoll Holdings PLC and Eyegate Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Innocoll Holdings PLC||-1,051.20%||N/A||-138.53%|
Eyegate Pharmaceuticals beats Innocoll Holdings PLC on 7 of the 10 factors compared between the two stocks.
About Innocoll Holdings PLC
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.
About Eyegate Pharmaceuticals
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
Receive News & Ratings for Innocoll Holdings PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings PLC and related companies with MarketBeat.com's FREE daily email newsletter.